GSPCROP
GSP Crop Science Limited
Agrochemicals manufacturer of formulations and intermediates
Commodities›Chemicals›Fertilizers & Agrochemicals›Pesticides & Agrochemicals
gspcrop.in(opens the company website in a new tab)Key metrics
Price as of 2026-10-16
Full years shown; sign in free for the trailing twelve months. Learn about these metrics →
Price & valuation
Share price and valuation multiples (P/E, P/B and more) over time.
Loading price history…
Compare with peers
Loading peers…
What you need to know
GSP Crop Science makes crop-protection chemicals, insecticides, herbicides, fungicides and plant growth regulators, in both the active ingredients (technicals) and the finished formulations that reach farmers, selling in India under its own brands and to business partners, and exporting to 37 countries.
Company snapshot
10thBy market cap
Ranked among 23 companies in Pesticides & Agrochemicals.
What we see
- ✗Return on equity is negative — the company is eroding shareholder value right now.
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Sales | 270 Cr | 402 Cr | 386 Cr |
| Operating expenses (approx.) | 257 Cr | 366 Cr | 343 Cr |
| EBITDA | 13 Cr | 36 Cr | 43 Cr |
| OPM % | 4.9% | 9.0% | 11.0% |
| Other income | 2 Cr | 9 Cr | 8 Cr |
| Interest | 10 Cr | 10 Cr | 7 Cr |
| Depreciation | 8 Cr | 8 Cr | 9 Cr |
| Profit before tax | -8 Cr | 27 Cr | 35 Cr |
| Tax % | 22.1% | 27.6% | 25.4% |
| Net profit | -6 Cr | 20 Cr | 26 Cr |
| EPS (₹) | ₹-1.38 | ₹5.09 | ₹5.67 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2026 | TTM |
|---|---|---|
| Sales | 1,517 Cr | Sign in free for the trailing twelve months |
| Operating expenses (approx.) | 1,332 Cr | Sign in free for the trailing twelve months |
| EBITDA | 185 Cr | Sign in free for the trailing twelve months |
| OPM % | 12.2% | Sign in free for the trailing twelve months |
| Other income | 14 Cr | Sign in free for the trailing twelve months |
| Interest | 37 Cr | Sign in free for the trailing twelve months |
| Depreciation | 30 Cr | Sign in free for the trailing twelve months |
| Profit before tax | 127 Cr | Sign in free for the trailing twelve months |
| Tax % | 25.5% | Sign in free for the trailing twelve months |
| Net profit | 95 Cr | Sign in free for the trailing twelve months |
| EPS (₹) | ₹24.93 | Sign in free for the trailing twelve months |
| Dividend payout % | 3.1% | Sign in free for the trailing twelve months |
The latest four quarters added up, next to each full year
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2026 |
|---|---|
| Equity capital | 47 Cr |
| Reserves | 725 Cr |
| Borrowings | 260 Cr |
| Other liabilities | 516 Cr |
| Total liabilities | 1,547 Cr |
| Fixed assets (net) | 215 Cr |
| CWIP | 48 Cr |
| Investments | 16 Cr |
| Loans & advances | 10 Cr |
| Inventories | 356 Cr |
| Trade receivables | 553 Cr |
| Cash & bank | 155 Cr |
| Other assets | 193 Cr |
| Total assets | 1,547 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2026 |
|---|---|
| Cash from operating activity | 59 Cr |
| Cash from investing | -75 Cr |
| Cash from financing | 152 Cr |
| Net cash flow | 137 Cr |
| Free cash flow (OCF − Capex) | -18 Cr |
Ratios
| Metric | Mar 2026 |
|---|---|
| ROCE % | 15.9% |
| ROE % | -0.4% |
| Debtor days | 133 |
| Inventory days | 139 |
| Days payable | 151 |
| Cash conversion cycle | 121 |
| OCF / EBITDA % | 32.1% |
| Debt / equity | 0.34 |
| Current ratio | 1.61 |
| Net debt / EBITDA | 0.57 |